CSP exam test prep questions and correct answers GRADED A+

CSP EXAM TEST PREP
QUESTIONS AND
CORRECT ANSWERS
GRADED A+ 2025-2026
PDC calculation - ANS-PDC = (# of unique days with supply / number of days in a
period) x 100


Which medication is a Jak inhibitor?
a. Humira (adalimumab)
b. Orencia (abatacept)
c. Actemra (toclizumab)
d. Xeljanz (tofacitinib) - ANS-d. Xeljanz (tofacitinib)


Which medication can elevate cholesterol?
a. Actemra (toclizumab)
b. Enbrel (etanercept)
c. Simponi (golimumab)
d. Kineret (anakinra) - ANS-a. Actemra (toclizumab)


Which shingles vaccine is safe to administer with TNF inhibitors?
a. Adacel
b. Zostavax
c. Shingrix
d. Varivax - ANS-c. Shingrix

,Most biologics increase the risk of infections, which of the following also increases the
risk of
neutropenia?
a. Rituxin (rituximab)
b. Taltz (ixekizumab)
c. Remicade (infliximab)
d. Cimzia (certolizumab pegol) - ANS-b. Taltz (ixekizumab)


Which psoriasis medication does not require screening for tuberculosis?
a. Stelara (ustekinumab)
b. Otezla (apremilast)
c. Cocentyx (seculinumab)
d. Humira (adalimumab) - ANS-b. Otezla (apremilast)


What is the standard starting dose for Taltz (ixekizumab) when used to treat psoriatic
arthritis?
a. 160mg subcutaneously once, followed by 80mg subcutaneously at weeks 2, 4, 6, 8,
10
and 12; then 80mg subcutaneously every 4 weeks
b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks
c. 160mg subcutaneously once, followed by 80mg subcutaneously every week for 4
weeks,
then 80mg every 4 weeks
d. 160mg subcutaneously once, followed by 80mg subcutaneously every other week -
ANS-b. 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks


A 45 y/o, 200lb patient is struggling with severe dermatitis and the provider wants to
potentially
start a biologic. Which medication would you recommend?
a. Protopic (tacrolimus)
b. Humira (adalimumab)
c. Stelara (ustekinumab)

, d. Dupixent (dupilumab) - ANS-d. Dupixent (dupilumab)


A 56 y/o, 140lb patient with psoriasis will be starting Stelara (ustekinumab), but the
provider
wants to verify the dosing of the medication. What starting dose would you
recommend?
a. Inject 45 mg subcutaneously at weeks 0 and 4, followed by 45 mg every 12 weeks
b. Inject 90 mg subcutaneously at weeks 0 and 4, followed by 90 mg every 12 weeks
c. Infuse 260 mg IV over at least 1 hour as a single dose, followed 8 weeks later with 90
mg
subcutaneously every 8 weeks
d. Infuse 520 mg IV over at least 1 hour as a single dose, followed 8 weeks later with
90 mg

subcutaneously every 8 weeks - ANS-a. Inject 45 mg subcutaneously at weeks 0 and 4,
followed by 45 mg every 12 weeks


Which of the following oral oncology medications does NOT require using caution in
patients
with hepatic impairment?
a. Votrient (pazopanib)
b. Ibrance (palbociclib)

c. Zytiga (abiraterone acetate)
d. Tykerb (lapatinib) - ANS-b. Ibrance (palbociclib)


Which side effect listed below is NOT a side effect of Zytiga (abiraterone acetate)?
a. Edema
b. Hot flush
c. Hepatotoxicity
d. Mucositis - ANS-d. Mucositis


A 45 year old male with pancreatic cancer is given a prescription for Tarceva
(erlotinib). He